1. Copyright © 2000 American Medical Association. All rights reserved.
From: Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Arch Intern Med. 2000;160(19): doi: /archinte
Figure Legend:
Twelve-month cumulative incidence (by survival analysis) of discontinuation due to gastrointestinal adverse events. Relative risk for rofecoxib vs nonsteroidal anti-inflammatory drugs (NSAIDs) is 0.70 (95% confidence interval, ).
Date of download: 10/14/2017
Copyright © 2000 American Medical Association. All rights reserved.

2. Copyright © 2000 American Medical Association. All rights reserved.
From: Gastrointestinal Tolerability of the Selective Cyclooxygenase-2 (COX-2) Inhibitor Rofecoxib Compared With Nonselective COX-1 and COX-2 Inhibitors in Osteoarthritis
Arch Intern Med. 2000;160(19): doi: /archinte
Figure Legend:
Twelve-month cumulative incidence (by survival analysis) of dyspeptic-type gastrointestinal adverse events. Six- and 12-month relative risks for rofecoxib vs nonsteroidal anti-inflammatory drugs (NSAIDs) are 0.85 (95% confidence interval, ) and 0.88 (95% confidence interval, ), respectively. Dyspeptic-type gastrointestinal adverse events included acid reflux, dyspepsia, epigastric discomfort, heartburn, nausea, and vomiting.
Date of download: 10/14/2017
Copyright © 2000 American Medical Association. All rights reserved.